Finally, when tested in an open-label study (226), a humanized recombinant IL6-R mAb (Tocilizumab) positively improved the clinical course of the disease and extraocular muscle motility in patients with steroid-resistant GO. This evidence concerns the gene IL6R and geroderma osteodysplastica.